SCHEMBL7197852

SCHEMBL7197852

COc1ccccc1OC1C(=O)NC(=S)NC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.49
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
CA2 P00918 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA4 P22748 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
MPO P05164 1/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
BRAF P15056 1/20 0.40
CHEK1 O14757 1/20 0.38
NAT1 P18440 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7209808 0.86 CA2 (0.46) ALDH1A1POLBCA2CA12CA1
SCHEMBL7293888 0.72 CA12 (0.35) ALDH1A1POLBCA2CA12CA1
SCHEMBL7303598 0.72 CA12 (0.35) ALDH1A1POLBCA2CA12CA1
SCHEMBL5257792 0.71 ALDH1A1 (0.43) SIRT2ALDH1A1POLBMEN1KMT2A
SCHEMBL7201836 0.71 CA12 (0.34) ALDH1A1POLBCA2CA12CA1
SCHEMBL627191 0.71 RAB9A (0.35) ALDH1A1POLBCA2CA12CA1
SCHEMBL7296783 0.71 DDB1 (0.37) ALDH1A1POLBCA2CA12CA1
SCHEMBL1532744 0.71 L3MBTL1 (0.39) SIRT2ALDH1A1POLBCA2CA12
SCHEMBL4062089 0.71 ALDH1A1 (0.46) ALDH1A1CA2CA12CA1CA4
SCHEMBL7330474 0.69 MAPT (0.33) ALDH1A1POLBCA2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596719-B1 Manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, and a method of treating a subject having a disorder involving endothelin with the compounds of the ACTELIO PHARMACEUTICALS LTD. (CH) 2003-07-22 US disclosed
EP-1137642-A1 BIS-SULFONAMIDES Actelion Pharmaceuticals Ltd. (CH) 2001-10-04 EP disclosed
WO-2001017976-A1 BIS-SULFONAMIDES ACTELION PHARMACEUTICALS LTD (CH) 2001-03-15 WO disclosed